-
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast CancerDaiichi Sankyo2024-03-25 10:05:10Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small
-
Daiichi Sankyo investiert ca. eine Milliarde Euro in Deutschland: Standort Pfaffenhofen (Bayern) wird zu internationalem Innovationszentrum ausgebautDaiichi Sankyo2024-02-15 11:44:37Daiichi Sankyo investiert ca. eine Milliarde Euro in Deutschland: Standort Pfaffenhofen (Bayern) wird zu
-
Declaration of Principle Supply Chain Due Diligence ActDaiichi Sankyo2024-01-11 10:13:05Declaration of Principle Supply Chain Due Diligence Act
-
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending LitigationDaiichi Sankyo2024-01-03 13:44:14Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including
-
VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AMLDaiichi Sankyo2023-11-09 08:10:56VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed
-
Change in Leadership at Daiichi Sankyo EuropeDaiichi Sankyo2023-11-06 08:21:48Change in Leadership at Daiichi Sankyo Europe
-
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung CancerDaiichi Sankyo2023-10-23 08:14:19ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced
-
Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AMLDaiichi Sankyo2023-09-15 16:13:51Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML
-
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung CancerDaiichi Sankyo2023-09-15 16:11:35ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung
-
ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 TrialDaiichi Sankyo2023-09-14 09:55:03ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung
